» Articles » PMID: 22858159

Epidemiological Surveillance of Myotonic Dystrophy Type 1: a 25-year Population-based Study

Overview
Specialty Neurology
Date 2012 Aug 4
PMID 22858159
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

This epidemiological study investigates the evolution of the prevalence and the phenotypes in a large cohort of myotonic dystrophy type 1 (DM1) patients living in the Saguenay-Lac-Saint-Jean (SLSJ) region (Quebec, Canada) over a 25-year period (1985-2010). In 1985, 406 patients with DM1 were known. From 1985 to 2010, 352 new DM1 patients were diagnosed and 321 patients died. During this period, we observed a significant ageing of the DM1 population, from a median age of 34.5years to 49.0years. The proportion of patients with an adult phenotype decreased significantly from 78% to 53% while the proportion of patients with a mild phenotype increased from 6% to 26%. Reasons for the ageing of the DM1 population and the changes in the distribution of DM1 phenotypes include the progressive lowering of total fertility rates over the last decades, a reduction of births at risk as a result of genetic counselling and prenatal diagnosis, and an increase in the number of mildly affected patients often recognised at an older age by predictive testing and molecular analysis. Although the DM1 prevalence remains very high in 2010 (158/100,000) in the SLSJ region, we observe a trend toward a decline in point prevalence rates over the last 10years.

Citing Articles

New Horizons in Myotonic Dystrophy Type 1: Cellular Senescence as a Therapeutic Target.

Legare C, Berglund J, Duchesne E, Dumont N Bioessays. 2024; 47(3):e202400216.

PMID: 39723693 PMC: 11848125. DOI: 10.1002/bies.202400216.


Latent factors underlying the symptoms of adult-onset myotonic dystrophy type 1 during the clinical course.

Zhang Y, Wallace B, Cai B, Johnson N, Ciafaloni E, Venkatesh Y Orphanet J Rare Dis. 2024; 19(1):409.

PMID: 39487453 PMC: 11529289. DOI: 10.1186/s13023-024-03359-8.


Molecular Pathology of Myotonic Dystrophy Type 1 in Iceland.

Hallgrimsdottir E, Svansson H, Stefansdottir V, Sveinsson O, Olafsdottir H, Briem E Mol Genet Genomic Med. 2024; 12(10):e70013.

PMID: 39373365 PMC: 11457208. DOI: 10.1002/mgg3.70013.


Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels.

Pierre M, Djemai M, Chapotte-Baldacci C, Pouliot V, Puymirat J, Boutjdir M Front Physiol. 2023; 14:1258318.

PMID: 37791351 PMC: 10544896. DOI: 10.3389/fphys.2023.1258318.


Targeting Myotonic Dystrophy Type 1 with Metformin.

Garcia-Puga M, Saenz-Antonanzas A, Matheu A, de Munain A Int J Mol Sci. 2022; 23(5).

PMID: 35270043 PMC: 8910924. DOI: 10.3390/ijms23052901.